DK1581251T3 - Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf - Google Patents

Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Info

Publication number
DK1581251T3
DK1581251T3 DK03808602.1T DK03808602T DK1581251T3 DK 1581251 T3 DK1581251 T3 DK 1581251T3 DK 03808602 T DK03808602 T DK 03808602T DK 1581251 T3 DK1581251 T3 DK 1581251T3
Authority
DK
Denmark
Prior art keywords
crystals
producing
methods
human growth
growth hormon
Prior art date
Application number
DK03808602.1T
Other languages
English (en)
Inventor
Chandrika Govardhan
Nazer Khalaf
Benjamin Paul Simeone
Original Assignee
Althea Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Althea Tech Inc filed Critical Althea Tech Inc
Application granted granted Critical
Publication of DK1581251T3 publication Critical patent/DK1581251T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
DK03808602.1T 2002-12-31 2003-12-31 Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf DK1581251T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43751902P 2002-12-31 2002-12-31
US51704203P 2003-11-03 2003-11-03
PCT/US2003/041545 WO2004060310A2 (en) 2002-12-31 2003-12-31 Human growth hormone crystals and methods for preparing them

Publications (1)

Publication Number Publication Date
DK1581251T3 true DK1581251T3 (da) 2016-06-27

Family

ID=32717908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03808602.1T DK1581251T3 (da) 2002-12-31 2003-12-31 Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Country Status (12)

Country Link
US (1) US9376479B2 (da)
EP (2) EP2460530A3 (da)
JP (2) JP4686361B2 (da)
KR (1) KR20050090430A (da)
AU (2) AU2003303646B2 (da)
BR (1) BR0317888A (da)
CA (1) CA2512052C (da)
DK (1) DK1581251T3 (da)
MX (1) MXPA05007181A (da)
RU (1) RU2357750C2 (da)
SG (1) SG176314A1 (da)
WO (1) WO2004060310A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
EP1663296A4 (en) * 2003-09-25 2009-11-25 Cangene Corp LIQUID FORMULATION OF HUMAN GROWTH HORMONE CONTAINING POLYETHYLENE GLYCOL
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
JP2008542235A (ja) * 2005-05-25 2008-11-27 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
EP1976551A4 (en) 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc COMPOSITIONS COMPRISING COMPLEX PROTEIN CRYSTALS BY POLYCATIONS AND PROCESSING METHOD THEREOF
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
PT2059260E (pt) * 2006-08-31 2013-09-03 Novartis Ag Composições farmacêuticas compreendendo hgh para distribuição oral
AU2007333959A1 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
JP5484041B2 (ja) * 2007-02-23 2014-05-07 学校法人関西学院 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
EP2078091A4 (en) * 2007-07-10 2010-09-01 Medimmune Llc CRYSTALS AND STRUCTURE OF THE VARIANT OF IGG FC HUMAN
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
JP5654498B2 (ja) * 2009-02-25 2015-01-14 スプラテック ファーマ インコーポレイテッド ベンダムスチン環状多糖組成物
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CA3076725A1 (en) 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015064591A1 (ja) * 2013-10-28 2015-05-07 テルモ株式会社 タンパク質水性懸濁剤
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
CN113827704B (zh) * 2015-10-16 2024-07-12 瑞泽恩制药公司 稳定蛋白质组合物
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
JP7104929B2 (ja) * 2017-07-24 2022-07-22 テルモ株式会社 医療用タンパク質とポリアミノ酸とを含む複合体の製造方法および医療用タンパク質とポリアミノ酸とを含む複合体
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
GB643268A (en) 1944-04-04 1950-09-15 Nordisk Insulinlab Improved process for the preparation of prolonged effect insulin products
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
EP0454044B1 (de) * 1990-04-25 1995-12-06 Hoechst Aktiengesellschaft Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff
AU636043B2 (en) 1990-06-04 1993-04-08 Schering Corporation Method for preparing interferon alpha-2 crystals
DK168790D0 (da) 1990-07-13 1990-07-13 Novo Nordisk As
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
JPH07503700A (ja) 1991-01-03 1995-04-20 アルカーメス　コントロールド　セラピューティックス，　インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
ES2185625T3 (es) 1991-12-20 2003-05-01 Novo Nordisk As Formulacion farmaceutica estabilizada que incluye hormona de crecimiento e histidina.
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
MD1699F2 (ro) 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
SE9302278D0 (sv) 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
WO1994012158A1 (en) * 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP0686045B1 (en) * 1993-02-23 2000-11-15 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5439643A (en) * 1993-11-03 1995-08-08 Liebert; Richard T. Method and apparatus for terminal sterilization
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5582591A (en) 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
ES2151079T3 (es) 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
JPH10511964A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6294656B1 (en) 1995-07-25 2001-09-25 Novartis Corporation Transforming growth factor β crystals
WO1997011178A1 (en) * 1995-09-21 1997-03-27 Genentech, Inc. Human growth hormone variants
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
ES2136458T3 (es) * 1996-06-14 1999-11-16 Takeda Chemical Industries Ltd Metodo para separar la metionina n-terminal.
ATE340259T1 (de) 1996-07-16 2006-10-15 Archibald James Mixson Kationisches vehikel: dns komplexe und ihre verwendung in gentherapie
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JP3884484B2 (ja) 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー 吸入用粒子の調製
SE9700566D0 (sv) 1997-02-18 1997-02-18 Pharmacia & Upjohn Ab Modified proteins
DK1009759T3 (da) 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
KR20010033268A (ko) 1997-12-18 2001-04-25 피터 지. 스트링거 결정형 테리파라타이드
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
EP1073421A1 (en) * 1998-04-27 2001-02-07 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6369118B1 (en) * 1998-09-09 2002-04-09 University Of Pittsburgh Biocompatible emulsifier
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DE60000622T2 (de) 1999-06-10 2003-02-27 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Einkapselung von kristallen mit mehrschichtigem überzug
EP1194128A2 (en) 1999-06-23 2002-04-10 Sedum Laboratories Ionically formulated biomolecule microcarriers
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US20040006473A1 (en) 2002-07-02 2004-01-08 Sbc Technology Resources, Inc. Method and system for automated categorization of statements
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US7037889B2 (en) 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
AU3938402A (en) 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2002053174A2 (en) * 2000-12-29 2002-07-11 Pbl Biomedical Laboratories Controlled release pharmaceutical systems
US6866359B2 (en) 2001-01-09 2005-03-15 Eastman Kodak Company Ink jet printhead quality management system and method
JP2005508360A (ja) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
PT1450847E (pt) 2001-11-13 2011-01-05 Genentech Inc Formulações de ligando de apo2/trail e suas utilizações
JP2005522488A (ja) * 2002-04-09 2005-07-28 大正製薬株式会社 味マスキングするための製剤
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them

Also Published As

Publication number Publication date
MXPA05007181A (es) 2006-04-07
EP2460530A3 (en) 2012-08-29
KR20050090430A (ko) 2005-09-13
WO2004060310A3 (en) 2004-12-09
EP1581251A2 (en) 2005-10-05
JP2010209079A (ja) 2010-09-24
AU2003303646B2 (en) 2010-03-04
EP1581251B1 (en) 2016-03-16
RU2357750C2 (ru) 2009-06-10
JP2006512416A (ja) 2006-04-13
WO2004060310A2 (en) 2004-07-22
CA2512052C (en) 2016-06-21
JP4686361B2 (ja) 2011-05-25
SG176314A1 (en) 2011-12-29
BR0317888A (pt) 2005-12-06
CA2512052A1 (en) 2004-07-22
AU2010201961A1 (en) 2010-06-03
US20040209804A1 (en) 2004-10-21
WO2004060310A8 (en) 2005-06-02
AU2003303646A1 (en) 2004-07-29
EP1581251A4 (en) 2009-03-04
US9376479B2 (en) 2016-06-28
RU2005124280A (ru) 2006-01-20
EP2460530A2 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
DK1581251T3 (da) Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1299323T3 (da) Gødningsmiddel med styret frigivelse og fremgangsmåde til fremstilling deraf
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1524710T3 (da) Tynd batteristruktur, batterienhed og fremgangsmåde til fremstilling af batterienhed
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
IS7467A (is) Lansóprasólfjölgervingar og aðferðir við að framleiða þá
IS7344A (is) Stýrð efnasmíði síprasídóns og samsetninga af því
DK1673104T4 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
GB2385328B (en) Crystals of glucokinase and methods of growing them
IS8061A (is) Kerfi og aðferð við að framleiða sérsniðna fóðringu fyrir gervilimi
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20035669D0 (no) Kvartsglassdigel og fremgangsmåte for fremstilling derav
DK1367501T3 (da) Leksikon med inddelte data og fremgangsmåde til anvendelse deraf
IL176089A0 (en) Modified macromolecules and methods of making and using thereof
DE50206171D1 (de) Knochenverankerungselement
DK1357025T3 (da) Skæreindretning og fremgangmåde til skæring
DK1261254T3 (da) Fremgangsmåde til kontrol af vækst af akvatiske planter og zoologiske organismer
IS2654B (is) Essítalópram hýdróbrómíð og aðferð til framleiðslu þess
EP1496110A4 (en) METHOD FOR PROLIFERATING HUMAN HEPATOCYTES AND METHOD FOR OBTAINING HUMAN HEPATOCYTES
DK1523243T3 (da) Mælkeproteinisolat og metode til fremstilling af samme
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK2305689T3 (da) Syntese af naturligt forekommende ecteinascidiner og relateredeforbindelser